Thus, a prospective clinical efficacy study that incorporates efavirenz PK parameters, as well as medication adherence and CYP2B6 genotypes in a predictive model for virologic response, is needed to inform strategies to optimize efavirenz-based ART in children with TB/HIV coinfection. The gene discussed is CYP2B6; the disease is coinfection.